학술논문

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (I-131) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies